{"filings":[{"id":1138517,"accession_number":"0001193125-26-275864","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2026-06-18T20:11:36+00:00","items":["5.07"],"status":"ready","headline":"Guardant Health annual meeting: say-on-pay proposal fails; directors elected, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Ian Clark and Manuel Hidalgo Medina elected with 70.5M and 81.9M votes for, respectively.","Ratification of Deloitte as auditor approved with 115.9M votes for, 15,250 against.","Advisory vote on executive compensation (say-on-pay) was not approved despite 98.2M for vs 9.9M against; broker non-votes 7.7M.","Stockholders selected one year as preferred frequency for future advisory votes on exec compensation (108.0M votes for one year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93791,"accession_number":"0001576280-26-000024","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q1 revenue rises 48% to $301.7 million, boosts 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue increased 48% to $301.7M driven by Oncology revenue growth of 36% and Screening revenue surge to $41.6M.","Net loss per share widened to $0.85 from $0.77; non-GAAP net loss per share improved to $0.45 from $0.49.","Raised 2026 revenue guidance to $1.30-$1.32B (32-34% growth), up from prior $1.25-$1.28B; Oncology volume growth expected >35%.","Shield screening tests reached 44,000 in Q1; 2026 Shield volume guidance raised to 230,000-245,000 tests.","Q1 adjusted EBITDA loss of $58.9M relatively flat; free cash flow burn $71.2M; cash position $1.2B."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":301665000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93790,"accession_number":"0001193125-26-182391","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Guardant Health CMO Craig Eagle resigns effective May 8, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Craig Eagle resigns as Chief Medical Officer, effective May 8, 2026.","No reason provided for resignation.","No replacement named at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105710,"accession_number":"0001576280-26-000012","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q4 revenue $281.3M (+39% YoY); 2026 revenue guided $1.25-1.28B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $281.3M (+39% YoY); Oncology tests 79k (+38%), Screening tests 38k.","Full year 2025 revenue $982.0M (+33%); net loss $416.3M ($3.32 EPS) vs $436.4M prior year.","Adj. EBITDA loss improved to $220.9M (FY) from $257.5M; free cash flow burn $233M vs $275M.","2026 guidance: revenue $1.25-1.28B (27-30% growth); Screening revenue $162-174M; volume 210k-225k tests.","Acquired MetaSight Diagnostics for $59M upfront plus up to $90M contingent consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":982021000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105709,"accession_number":"0001576280-26-000004","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Guardant Health reports Q4 revenue $280M (+39% YoY); full year revenue $981M (+33%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 oncology tests ~79,000 (+38% YoY); full year ~276,000 (+34%).","Shield screening tests surged to ~38,000 in Q4 (vs 6,400 prior year).","Preliminary free cash flow: -$54M Q4, -$233M full year.","Cash and marketable securities ~$1.3B as of Dec 31, 2025.","Results are preliminary and unaudited; final audited results expected Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":982021000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121984,"accession_number":"0001193125-25-272592","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Guardant Health raises ~$717M via upsized equity and convertible debt offerings","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Public offering of 3,833,332 shares at $90/share (incl. underwriter option), net proceeds ~$327.2M.","Convertible notes: $402.5M principal, 0% coupon, due 2033, conversion price ~$121.50/share (35% premium).","Net proceeds from notes ~$390M; combined ~$717M for general corporate purposes, including possible 2027 note repurchase.","Both offerings upsized from initially announced amounts ($250M equity, $300M notes); closed Nov 7, 2025.","Notes convertible under certain conditions after Feb 15, 2033; redeemable after Nov 20, 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121983,"accession_number":"0001576280-25-000276","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q3 revenue $265.2M (+39% YoY); raises FY2025 revenue guidance to $965-$970M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $265.2M (+39% YoY); GAAP net loss $92.7M ($0.74/share), non-GAAP net loss $48.3M ($0.39/share).","Oncology revenue $184.4M (+31%), 74K tests (+40%); Shield screening revenue $24.1M (from $1M), 24K tests.","FY2025 revenue guidance raised to $965-$970M (from $915-$925M), ~31% YoY growth; Screening rev guidance $71-$73M.","Non-GAAP gross margin 66% (up from 63%); cash, equivalents and restricted cash $689.5M.","Shield expanded to multi-cancer detection; Guardant360 Liquid PMA submitted to FDA; new collaborations with Quest and PathGroup."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":700755000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138694,"accession_number":"0001576280-25-000269","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Guardant Health to host Investor Day on September 24, 2025","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Investor Day scheduled for Sept 24, 2025 at 9:00 a.m. ET in New York City.","Presentation by co-CEOs Helmy Eltoukhy and AmirAli Talasaz and executive team.","Company will highlight operations, strategic priorities, and financial outlook.","Live and archived webcast available on Guardant Health's investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138693,"accession_number":"0001576280-25-000267","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Former HHS Secretary Alex Azar appointed to Guardant Health board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alex M. Azar II appointed to Guardant Health board effective Sept 12, 2025; board size increased to 11.","Azar will receive standard non-employee compensation: stock option and RSU each valued at $362,500.","Azar previously served as 24th HHS Secretary (2018-2021) and President of Lilly USA.","Appointed to the nominating and corporate governance committee of the board.","Chairman Helmy Eltoukhy cited Azar's deep operating experience in government and private sector."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138692,"accession_number":"0001576280-25-000245","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q2 revenue $232.1M (+31% YoY); raises FY2025 guidance to $915-925M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $232.1M (+31% YoY); Oncology $158.7M (+22%), Screening $14.8M, Biopharma $56.0M (+28%).","Non-GAAP gross margin 66% (vs 60% YoY); net loss $99.9M ($0.80) vs $102.6M ($0.84) YoY.","2025 revenue guidance raised to $915-925M (24-25% growth) from prior $880-890M; non-GAAP gross margin guidance 63-64%.","Shield screening test volume expected 68,000-73,000; Screening revenue guidance raised to $55-60M.","Free cash flow burn -$65.9M in Q2 vs -$99.1M; core business ex-Screening on track for FCF breakeven in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":435559000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156141,"accession_number":"0001193125-25-143681","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Guardant Health shareholders elect all four director nominees at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Vijaya Gadde, Roberto Mignone, Myrtle Potter, and Musa Tariq elected with 96M, 97M, 97M, and 70M votes for respectively.","Deloitte & Touche LLP ratified as independent auditor for FY2025 with 105.6M votes for, 24.5K against.","Advisory say-on-pay proposal approved with 91.2M for, 7.0M against, and 364K abstentions.","Broker non-votes of 7.2M shares on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156140,"accession_number":"0001576280-25-000135","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q1 revenue $203.5M (+21% YoY); raises FY2025 revenue guidance to $880-$890M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $203.5M, +21% YoY; oncology $150.6M (+20%, 59K tests); screening $5.7M (9K Shield tests); biopharma $45.4M (+21%).","Net loss $95.2M ($0.77/sh) vs $115.0M loss year ago; non-GAAP net loss $61.1M ($0.49/sh); cash $803.9M.","FY2025 revenue guidance raised to $880-$890M (+19-20% YoY) from $850-$860M; screening revenue guided $40-$45M (from $25-$30M).","Non-GAAP gross margin guided 62-63%; FCF burn expected $225-$235M; ex-screening business on track for FCF breakeven in Q4 2025.","Shield received CMS ADLT status ($1,495/test) and VA network coverage covering 9M lives; launched upgraded Guardant360 Tissue test."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":203471000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156139,"accession_number":"0001193125-25-076885","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Guardant Health extends Redwood City lease through 2030/2031; total ~$50M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Third Amendment to lease with Metropolitan Life Insurance Co.; extends term to Dec 31, 2030 or 2031 per building.","Base rent increases 3% annually from 2026; total lease value approximately $50 million.","Annual lease expense will not be materially changed by the amendment.","Original lease dated November 2014; previously amended in October 2017 and March 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174584,"accession_number":"0001576280-25-000043","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q4 revenue up 30% to $201.8M; 2025 revenue guidance $850-860M, convertible debt exchanged","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 revenue $739M (+31% YoY); net loss $436.4M ($3.56 loss per share); non-GAAP net loss $247.2M ($2.01 loss per share).","Q4 2024 revenue $201.8M (+30% YoY); net loss $111M ($0.90 loss per share); non-GAAP net loss $77.3M ($0.62 loss per share).","Completed convertible debt exchange: issued $600M 1.25% 2031 notes, retiring $659.3M of 0% 2027 notes; also repurchased $45M of common stock.","2025 guidance: revenue $850-860M (15-16% growth); oncology clinical volume growth expected to accelerate to ~25%; screening revenue $25-30M on 45-50K Shield tests.","Free cash flow burn improved to $275M in 2024; expects $225-235M in 2025; Guardant Reveal received Medicare coverage for CRC surveillance."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":739016000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174583,"accession_number":"0001193125-25-027362","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Guardant Health issues $600M 1.25% convertible notes due 2031; retires $659.3M of 0% notes due 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $600M new 1.25% convertible notes due 2031 for $659.3M of existing 0% notes due 2027.","After close, $490.7M of 2027 notes remain outstanding; new notes mature Feb 15, 2031.","Initial conversion price ~$62.22/share (35% premium to Feb 6 closing price).","Up to 13,017,960 shares may be issued upon conversion based on initial max conversion rate.","New notes are senior unsecured; interest payable semi-annually at 1.25%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174582,"accession_number":"0001193125-25-022242","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Guardant Health exchanges $659.3M of 0% 2027 notes for $600M of 1.25% 2031 notes; plans $45M buyback","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issues $600M of 1.25% Convertible Senior Notes due Feb 15, 2031, exchanging for $659.3M of 0% Convertible 2027 Notes.","Initial conversion price of new notes ~$62.22/share, a 35% premium to Feb 6, 2025 closing price.","After close (~Feb 14, 2025), $490.7M of 2027 Notes remain outstanding with unchanged terms.","Intends to repurchase ~$45M of common stock from participants; exchange agent will buy ~$35M separately.","New notes are unregistered, issued under Section 4(a)(2) and 3(a)(9) exemptions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174581,"accession_number":"0001193125-25-005319","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Guardant Health reports preliminary Q4 revenue ~$200M (+29% YoY); FY24 revenue $737M (+31%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue Q4 ~$200M (+29% YoY); full year ~$737M (+31% YoY).","Oncology clinical tests (ex-Shield) Q4 57,300 (+24%); full year 206,700 (+20%).","Biopharma tests Q4 11,050 (+16%); full year 40,500 (+35%).","Shield screening tests Q4 6,400 with ~$4M revenue in first full commercial quarter.","Free cash flow -$84M in Q4, -$275M full year; cash & securities $944M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":739016000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191543,"accession_number":"0001576280-24-000260","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q3 revenue $191.5M (+34% YoY); raises FY 2024 revenue guidance to $720-725M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $191.5M (+34% YoY); GAAP net loss $107.8M ($0.88/shr), Non-GAAP net loss $55.0M ($0.45/shr).","Clinical test volume 53,100 (+21%), biopharma 10,500 (+40%); Guardant360 ASP >$3,000.","Full-year 2024 revenue guidance raised to $720-725M (prior $690-700M), growth 28-29%.","Free cash flow guidance improved to $(265)-$(275)M, improvement of $70-80M vs 2023.","Shield IVD launched; received Medicare pricing of $920; CMS removed cost-sharing for follow-on colonoscopy."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":537202000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191542,"accession_number":"0001193125-24-242960","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Guardant appoints Roberto Mignone (Bridger Management) to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Guardant expands board to 10; appoints Roberto Mignone as Class I director effective Oct 21, 2024.","Founder and Managing Partner of Bridger Management, a healthcare-focused investment firm.","Appointed to audit committee; receives initial equity awards totaling $725,000 vesting over 4 years.","Appointment follows FDA approval of Shield blood test for early-stage colorectal cancer screening.","Also serves on Teva Pharmaceuticals board and as co-Vice Chairman of NYU Langone Medical Center."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208020,"accession_number":"0001193125-24-206179","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Guardant Health enters ATM sales agreement with Jefferies for up to $400M equity offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Open Market Sale Agreement with Jefferies LLC for at-the-market offering of common stock.","Aggregate gross proceeds of up to $400 million; agent compensation up to 3% of gross sales price.","Shares sold under existing shelf registration (Form S-3 filed May 2023); prospectus supplement filed Aug 23, 2024.","Company has no obligation to sell any shares; may suspend or terminate the program at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208019,"accession_number":"0001576280-24-000189","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q2 revenue up 29% to $177.2M, raises FY2024 guidance; FDA approves Shield CRC test","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $177.2M (+29% YoY); precision oncology revenue $166.5M (+33%).","GAAP net loss $102.6M ($0.84/share); non-GAAP net loss $58.5M ($0.48 loss).","FY2024 revenue guidance raised to $690-700M (prior $675-685M), growth 22-24%.","Shield blood test received FDA approval for first-line CRC screening; commercial launch; Medicare covers 45M beneficiaries.","Clinical tests 49,400 (+14%), biopharma tests 10,475 (+56%); cash $1.0B."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":345726000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208018,"accession_number":"0001193125-24-186674","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Guardant Health's Shield blood test gets FDA approval for colorectal cancer screening in ages 45+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Shield is first blood test approved by FDA as a primary screening option for colorectal cancer.","Meets CMS requirements for Medicare coverage; expected to be covered for eligible Medicare beneficiaries.","ECLIPSE study showed 83% sensitivity for CRC detection and 90% specificity for advanced neoplasia.","Real-world adherence rate for Shield is over 90%, compared to 28-71% for other screening methods.","Company to launch test soon; commercial insurance coverage expected after future guideline inclusion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208017,"accession_number":"0001193125-24-181093","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Guardant Health appoints Dr. Manuel Hidalgo Medina to board effective July 17","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased to nine seats; Dr. Hidalgo appointed as Class II director, term expiring at 2026 annual meeting.","Dr. Hidalgo is Chief of Hematology/Medical Oncology at Weill Cornell Medicine and also serves on Bristol-Myers Squibb's board.","Received standard non-employee director compensation: stock option and RSU awards each valued at $362,500, vesting over four years.","Appointed to the nominating and corporate governance committee of the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225555,"accession_number":"0001193125-24-161223","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Guardant Health shareholders reject advisory say-on-pay; director Krognes gets 28% withhold votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Advisory vote on named executive officer compensation failed: 84.6M for, 5.8M against, 0.6M abstain.","Director nominee Steve Krognes received 64.4M for and 25.6M withheld (approx 28% withhold).","Other directors Eltoukhy and Talasaz elected with >98% votes for; auditor ratification approved.","Say-on-pay is non-binding but signals shareholder discontent; Krognes opposition notable.","Meeting held June 12, 2024; broker non-votes on director and say-on-pay were 6.2M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225554,"accession_number":"0001193125-24-151836","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Guardant Health amends executive severance plan with enhanced benefits for Co-CEOs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment approved May 24, 2024; applies to all executives including named officers.","Non-CIC termination: 12 months base salary (lump sum), prorated target bonus, 12 months COBRA.","CIC termination: 18 months salary (24 for Co-CEOs), full target bonus, full equity vesting.","Co-CEOs' 2024 long-term awards vest fully on termination before 2026; PSUs vest at up to 250% target if CIC before 2025.","Co-CEOs receive annual RSU/PSU awards in lieu of salary and bonus; severance reflected in accelerated vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225553,"accession_number":"0001193125-24-146510","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA advisory panel strongly recommends approval of Guardant's Shield blood test for CRC screening","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA advisory panel voted 8-1 that Shield is safe, 6-3 that it is effective, and 7-2 that benefits outweigh risks.","Shield blood test showed 83% sensitivity for colorectal cancer detection and 90% specificity for advanced neoplasia in ECLIPSE study.","FDA decision on premarket approval expected later in 2024; Shield is on track to become first FDA-approved blood test for CRC screening.","Approximately 50 million eligible Americans are not up-to-date with CRC screening; Shield offers a blood-draw alternative to stool-based tests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225552,"accession_number":"0001576280-24-000108","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q1 revenue up 31% to $168.5M; raises 2024 revenue guidance to $675-685M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $168.5M (+31% YoY); net loss narrowed to $115M ($0.94 loss per share) from $133.5M.","Precision oncology revenue $156.2M (+38%); clinical tests +20%, biopharma tests +37%.","2024 revenue guidance raised to $675-685M (prior $655-670M); FCF guidance improved to $(275)-$(285)M.","Non-GAAP gross margin ex-screening guided to 61%-63% (prior 60%-62%).","ECLIPSE published in NEJM; FDA Advisory Committee on May 23; Shield IVD launch expected post-approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":168491000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244716,"accession_number":"0001193125-24-075436","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Guardant Health co-CEOs receive new annual and long-term equity grants; base salary remains $1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Each co-CEO gets annual RSU and PSU awards with $800,000 target value each, in lieu of salary and bonus.","2024 long-term awards: $5M RSU and $5M PSU per co-CEO, vesting over three years with performance metrics.","Founders PSU award from May 2020 cancelled as part of new agreement.","Base salary stays at $1; severance plan Tier 1 continues but cash severance based on $1 salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244715,"accession_number":"0001576280-24-000039","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q4 rev $155.1M (+22% YoY); GAAP net loss $187.0M incl $83.4M legal accrual; 2024 guidance $655-670M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fourth quarter 2023 revenue $155.1M, up 22% YoY; full year revenue $563.9M, up 25%.","GAAP net loss Q4 $187.0M ($1.58 per share) vs $139.9M ($1.36) prior year, including $83.4M non-recurring legal accrual.","Clinical test volume 46,400 in Q4 (+29% YoY); full year 172,900 (+39% YoY).","2024 revenue guidance $655-670M (16-19% growth); non-GAAP op expense $740-750M; free cash flow -$320 to -$330M.","Cash and marketable securities $1.2B at year-end; Shield PMA submission under FDA review, expect FDA approval and launch in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":563948000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244714,"accession_number":"0001193125-24-021871","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Guardant Health director Samir Kaul resigns; board size reduced to 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Samir Kaul resigned from the board and compensation committee, effective Feb 1, 2024.","Resignation not due to any dispute or disagreement with the company or board.","Board size reduced from nine to eight directors effective upon his resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244713,"accession_number":"0001193125-24-004446","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Guardant Health reports preliminary 2023 revenue ~$562-563M (+25% YoY); clinical test volumes up 39%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2023 revenue $562-563M, up 25% YoY; clinical test volume 172,900 (+39%).","Q4 2023 revenue $153-154M (+21%); clinical tests 46,400 (+29%).","Full year free cash flow approx. -$347M; cash and equivalents $1.2B as of Dec 31, 2023.","Co-CEOs cite Shield blood test progress; expect FDA approval and IVD launch in 2024.","Results are preliminary and unaudited; final audited results expected in February 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":563948000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262157,"accession_number":"0001193125-23-301187","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Guardant Health raises $90.7M in registered direct offering with Baillie Gifford","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$90.7M gross via 3,387,446 shares sold at $26.77 each to Baillie Gifford-managed accounts.","Net proceeds ~$90.6M; funds earmarked for general corporate purposes including working capital and capex.","Offering closed Dec 21, 2023; executed under effective shelf registration statement on Form S-3.","CEO Helmy Eltoukhy noted strong support from Baillie Gifford as Guardant expands precision oncology portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262156,"accession_number":"0001193125-23-298718","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Guardant Health announces March 28, 2024 FDA panel review date for Shield colorectal cancer blood test","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA's Molecular and Clinical Genetics Panel tentatively set to review Shield PMA on March 28, 2024, subject to confirmation.","Shield blood test data derived from ECLIPSE study of over 20,000 average-risk adults for colorectal cancer detection.","Co-CEO AmirAli Talasaz states proposed timing aligns with completing PMA process and launching Shield IVD in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262155,"accession_number":"0001193125-23-277418","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Guardant Health hit with $83.4M patent infringement verdict; will appeal","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury found willful infringement of two patents; awarded $83.4M in damages (6% royalty on past sales).","Plaintiffs may seek up to treble damages (≈$250M) based on the willfulness finding.","Guardant strongly disagrees, plans post-trial motions and appeal to Federal Circuit.","Company says verdict unlikely to materially impact business but may require future royalty payments if upheld.","Case: TwinStrand Biosciences, Inc. and Univ. of Washington v. Guardant Health, C.A. No. 21-1126-GBW-SRF."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262154,"accession_number":"0001576280-23-000186","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q3 revenue $143M (+22% YoY); raises FY 2023 guidance to $553-556M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $86.1M ($0.73/share) vs $162M ($1.58) YoY; non-GAAP loss $79.2M ($0.67).","Clinical test volume 43,900 (+35% YoY); biopharma tests 7,500 (+11%).","Precision oncology revenue up 31% YoY; Medicare appeal payment of $3.6M included.","FY 2023 revenue guidance raised to $553-556M (23-24% growth); cash $1.2B.","Launched Guardant360 in Japan/China; Japan approval as CDx for ENHERTU."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":408894000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262153,"accession_number":"0001193125-23-270502","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Guardant Health COO Ines Dahne-Steuber resigns effective Nov 10, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ines Dahne-Steuber resigns as COO, effective November 10, 2023.","She will remain employed through December 1, 2023 to assist with transition.","No successor or permanent replacement has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279367,"accession_number":"0001193125-23-230106","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Guardant Health holds Investor Day with co-CEOs to update on strategy and financial outlook","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor Day on September 7, 2023, in NYC; remarks from co-CEOs Helmy Eltoukhy and AmirAli Talasaz.","Management to highlight operations and provide updates on key strategic priorities and financial outlook.","No specific financial figures or guidance changes disclosed in this filing; presentation content not provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279366,"accession_number":"0001576280-23-000121","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q2 revenue $137.2M (+26% YoY); raises FY2023 revenue guidance to $545-550M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $137.2M (+26% YoY); clinical test volume 43,500 (+49%), biopharma tests 6,700 (+12%).","Net loss $72.8M vs $229.4M prior year (includes fair value changes); Non-GAAP net loss $88.7M.","Raised FY2023 revenue guidance to $545-550M (from $535-545M); expects operating expenses below 2022 levels.","Cash $1.2B; completed public offering raising $381M net; Guardant360 now covered by all major U.S. commercial insurers."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":265864000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279365,"accession_number":"0001193125-23-200555","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Guardant settles Illumina litigation, extends commercial partnership with three-year agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Guardant and Illumina agreed to dismiss with prejudice the March 2022 Delaware lawsuit, including all IP allegations.","New three-year collaboration covers sharing of specimen samples for cancer research and a long-term purchase/supply commitment.","The agreement extends the companies' longstanding commercial relationship; no financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297739,"accession_number":"0001193125-23-170137","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Guardant Health stockholders elect all three director nominees and approve auditor and say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ian Clark, Meghan Joyce, and Samir Kaul elected directors; Clark received 48.4M for, 29.2M withheld.","Ratification of Deloitte & Touche as auditor: 84.0M for, 26,878 against, 32,392 abstain.","Advisory vote on executive compensation approved: 66.9M for, 10.5M against, 178,806 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297738,"accession_number":"0001193125-23-154198","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Guardant Health closes $380.5M equity offering of 14.375M shares at $28.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 14.375M shares including full exercise of underwriters' option for net proceeds ~$380.5M.","Public price $28.00/share; underwriters paid $26.53/share.","Directors and officers subject to 60-day lock-up on share sales.","Offering completed on May 25, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297737,"accession_number":"0001576280-23-000059","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q1 revenue up 34% to $128.7M; raises FY2023 guidance to $535-545M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $128.7M (+34% YoY); clinical tests 39,100 (+45%), biopharma tests 6,150 (+21%).","Net loss $133.5M ($1.30/share) vs $123.2M ($1.21) prior year; non-GAAP net loss $108.5M ($1.06).","Gross margin 59% (down from 67%) on mix shift; operating expenses $209.7M (+12%).","FY2023 revenue guidance raised to $535-545M (prev $525-540M); expects FCF outflow ~$350M.","Appointed Ines Dahne-Steuber COO and promoted Darya Chudova CTO; Shield CRC screening PMA under FDA review."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":128714000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297736,"accession_number":"0001193125-23-139104","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Guardant Health reports Shield test 83% sensitivity, 90% specificity for CRC in ECLIPSE study at DDW","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shield blood test achieved 83% overall sensitivity and 90% specificity in detecting colorectal cancer in average-risk adults.","Sensitivity of 55% for Stage I, 100% for Stages II, III, and IV; 81% for Stages I-III, 72% for localized (Stage I-II).","Real-world adherence rate for Shield exceeds 90% since commercial launch in May 2022.","Study enrolled diverse population: 13% Black, 15% Hispanic, 7% Asian American.","Data suggests Shield could detect CRCs at curable stage and help close screening gap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297735,"accession_number":"0001193125-23-138306","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Guardant Health names Ines Dahne-Steuber COO, promotes Darya Chudova to CTO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ines Dahne-Steuber appointed COO effective May 3, 2023; previously senior exec at Fresenius Medical Care.","Compensation: $490k base salary, 50% target bonus, ~$2M in RSUs and ~$2M in stock options (four-year vesting).","Signing bonus of $50k and relocation allowance up to $50k, subject to 12-month clawback.","Darya Chudova promoted to CTO; led development of Shield blood-based colorectal cancer screening technology.","Both appointments effective May 2023, aiming to scale global operations and support product launches."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297734,"accession_number":"0001576280-23-000049","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Guardant Health replaces EY with Deloitte as independent auditor; no disagreements cited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee approved dismissal of Ernst & Young and engagement of Deloitte effective April 4, 2023.","EY's audit reports for FY2022 and FY2021 were unqualified with no adverse opinion.","No disagreements or reportable events occurred during the past two fiscal years or subsequent interim period.","EY agreed with the disclosures in a letter dated April 10, 2023, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318002,"accession_number":"0001576280-23-000036","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Guardant Health confirms no deposits or investments at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aware of FDIC takeover of SVB due to liquidity concerns.","Guardant does not hold any deposits or investments at SVB.","No financial exposure to SVB collapse; operations unaffected.","Disclosure made under Regulation FD on March 10, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318001,"accession_number":"0001193125-23-050767","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Guardant Health appoints Musa Tariq to board of directors effective March 6, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Musa Tariq appointed as Class I director effective March 6, 2023; term expires at 2025 annual meeting.","Tariq is CMO of GoFundMe; previously held marketing leadership at Airbnb, Ford, Apple, Nike, Burberry.","Appointed to nominating and corporate governance committee.","Receives initial stock option and RSU awards each valued at $362,500, vesting over four years.","No arrangements or transactions requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318000,"accession_number":"0001576280-23-000019","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q4 revenue $126.9M (+17% YoY); net loss widens to $139.9M; guides FY23 rev $525-540M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $126.9M (+17% YoY); full-year revenue $449.5M (+20% YoY).","Q4 clinical test volume 36,000 (+41% YoY); biopharma 8,200 (+24% YoY).","Q4 net loss $139.9M ($1.36/share) vs $90.9M ($0.89) prior year; non-GAAP net loss $119.6M.","FY23 revenue guidance $525-540M (17-20% growth); expects free cash outflow ~$350M.","ECLIPSE study for Shield CRC screening showed 83% sensitivity, 90% specificity; FDA approved Guardant360 CDx for breast cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":449538000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317999,"accession_number":"0001576280-23-000005","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Guardant Health prelim FY22 revenue $447-450M, up 20%; test volumes up >40% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY22 revenue $447M-$450M, up 20% YoY; Q4 revenue $124M-$127M, up 15-17%.","FY22 clinical test volumes 124,800 (+42% YoY); biopharma tests 26,000 (+40% YoY).","Q4 clinical tests 36,000 (+41% YoY); biopharma tests 8,200 (+24% YoY).","Cash, equivalents and marketable debt securities $1.0B as of Dec 31, 2022.","Positive ECLIPSE trial readout for Shield blood-based colorectal cancer test; expanding to lung cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":449538000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336264,"accession_number":"0001576280-22-000118","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2022-12-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Guardant Health ECLIPSE blood test shows 83% sensitivity for colorectal cancer in 20,000+ patient study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ECLIPSE study: 83% sensitivity for CRC detection, 90% specificity vs. negative colonoscopy.","Advanced adenoma sensitivity at 13%; cfDNA-only test outperformed cfDNA+protein version.","Plans PMA submission to FDA in Q1 2023; results exceed CMS reimbursement criteria.","Blood test completion rate 90% vs. 43-66% for stool tests; aims to address 49M unscreened adults.","Guardant expands test to other cancers including lung cancer; co-CEO cites breakthrough in blood-based screening."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-12-15T23:59:59+00:00|336264"}